TBI (TrueBlue, Inc.) — AI Stock Analysis & Recommendation

Research of September 10, 2026 · Industrials / Services-Help Supply Services

TradeFlare's AI research teams rate TBI a HOLD. The latest price is $9.72.

The research plan

• Entry: $9.07
• Time horizon: days

The current setup does not warrant a buy.

Why

The current setup does not warrant a buy. Catalysts to watch: No immediate catalysts identified to overcome fundamental and risk concerns; The scanner trigger is based on a short-term mean-reversion signal that is not supported by other teams; The neutral market regime does not provide a tailwind for speculative trades. Key risks: Significant fundamental weakness with negative margins, debt burden, and negative free cash flow; High risk score (8/10) due to deep drawdown, negative operating cash flow, and high volatility; Conflicting technical signals and a neutral technical verdict, which is not bullish.

What could push TBI higher

• No immediate catalysts identified to overcome fundamental and risk concerns.
• The scanner trigger is based on a short-term mean-reversion signal that is not supported by other teams.
• The neutral market regime does not provide a tailwind for speculative trades.

Key risks for TBI

• Significant fundamental weakness with negative margins, debt burden, and negative free cash flow.
• High risk score (8/10) due to deep drawdown, negative operating cash flow, and high volatility.
• Conflicting technical signals and a neutral technical verdict, which is not bullish.

What each AI research team found

Fundamental team: Bearish · valuation: speculative

TrueBlue is fundamentally weak due to persistent unprofitability, negative cash flows, and a high debt burden, despite positive revenue growth. The current valuation appears speculative given these significant financial challenges and lack of analyst conviction, suggesting a bearish outlook.

• TrueBlue (TBI) is experiencing significant profitability challenges with negative net margins (-3.35% TTM) and negative operating cash flow (-$54.49 million TTM), indicating a fundamental inability to generate cash from core operations.
• The company carries a substantial debt burden with a high debt-to-equity ratio of 54.36%, coupled with negative free cash flow (-$67.44 million TTM), raising serious concerns about its financial health and ability to service its debt.
• Despite positive revenue growth (11.8% YoY), this top-line momentum is not translating into profitability, suggesting operational inefficiencies or intense competitive pressures.

Technical team: Neutral

The analysis presents conflicting signals, with the Trend Analyst indicating an uptrend while the Momentum Analyst points to strong bearish momentum. The lack of clear support/resistance and undefined price levels further contribute to a neutral outlook. Further clarity is needed before establishing a directional bias.

• The TBI chart shows an uptrend with price above key moving averages, but recent bearish candlestick patterns suggest caution and a need for further confirmation before entering a trade.
• TBI is trading sideways with mixed volume signals, lacking clear support or resistance, suggesting a neutral short-term outlook.
• All indicators suggest strong bearish momentum, with RSI and Stochastic in oversold territory and MACD showing a bearish crossover, indicating a potential continuation of the downtrend.

Sentiment team: Neutral

TrueBlue (TBI) exhibits a neutral sentiment across news, social media, and analyst views, reflecting a balance between strong Q2 performance and concerns about potential overvaluation. While recent earnings and technical momentum are positive, the lack of near-term catalysts and mixed analyst opinions suggest a stable, but not strongly trending, outlook.

• Media coverage is predominantly neutral, with a slight positive lean driven by strong Q2 earnings results and reaching a 2-year high, though some concerns about overvaluation and Q2 net loss persist. (Score: 0.021)
• Neutral sentiment driven by positive Q2 earnings and strong recent performance, but concerns about mixed analyst opinions and potential overvaluation temper enthusiasm. (Score: 0.021)
• Mixed analyst sentiment with positive technical momentum and increased institutional ownership, but concerns remain regarding potential overvaluation and a lack of immediate earnings catalysts. (Consensus: NEUTRAL)

Risk team: High

TBI presents a high-risk profile due to its significant historical drawdown, persistent negative cash flow and net income, and high volatility. The low liquidity further exacerbates these risks, making it difficult to manage positions effectively. A small position size with a tight stop-loss is recommended.

• Deep Drawdown (1Y): The stock has experienced a significant price decline of -85% over the past year, indicating substantial volatility and potential underlying issues.
• Negative Operating Cash Flow: The company consistently generates negative operating cash flow, which is unsustainable in the long run and points to fundamental operational challenges.
• High Volatility: Annualized volatility is very high, suggesting significant price swings and unpredictable returns.

TBI at a glance

Market value	$252.1M
Debt / equity	0.32

Every AI call on TBI since September 4, 2026, and what happened next (5 calls) →

Research of September 10, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.